Search

Displaying results 3091 - 3100 of 5925 in total
  1. Drug

    Iobutoic acid

    go.drugbank.com/drugs/DB21443
    Experimental

    Iobutoic acid has a monoisotopic molecular weight of 670.82 Da.

  2. Drug

    TU-100

    go.drugbank.com/drugs/DB12467
    Investigational

    TU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.

  3. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

    Synonyms: 2-(p-Butoxyphenyl)-acetohydroxamic acid, p-Butoxyphenylacetohydroxamic acid
  5. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.

  6. Drug

    Benzthiazide

    go.drugbank.com/drugs/DB00562
    Approved

    Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity.

  7. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA.

  8. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia due

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  10. Drug

    Methylcellulose

    go.drugbank.com/drugs/DB11228
    ApprovedInvestigational

    The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values